Korea Exchange (KRX) said on the 4th that it promoted listings of European corporations on KOSDAQ and the Korean capital market at the global bio conference "BIO-Europe 2025" in Austria.
On the 3rd, Korea Exchange (KRX) hosted the Korea Capital Market Spotlight event for global bio executives and employees. The exchange introduced KOSDAQ to about 150 attendees and provided guidance on KOSDAQ initial public offering (IPO) matters, including listing procedures.
Korea Exchange (KRX) also held one-on-one meetings with foreign bio corporations participating in BIO-Europe to brief them on KOSDAQ market trends and listing procedures.
IPO specialist institutions explained trends in Korea's venture capital (VC) industry, analyses of IPO listing cases, and accounting and legal issues related to listings. In investment banking (IB), Samsung and Eugene Securities participated; on the VC side, Korea Investment Partners, KB Investment, and Intervest took part. BAE, KIM & LEE LLC and Samil and The-All accounting firms also joined.
The conference also featured networking events between domestic and foreign institutions and corporations. The Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the Korea Health Industry Development Institute, and the Korea Institute of Toxicology (KIT) attended.
KOSDAQ Market Deputy Minister Min Kyung-uk said, "KOSDAQ is a platform that helps venture corporations with strong technological capabilities raise funds and grow," adding, "KOSDAQ will continue to establish itself as a global innovative technology stock market where innovative corporations can grow by improving entry and exit systems and taking other steps."